Summary

Eligibility
for people ages 50-70 (full criteria)
Location
at Irvine, California and other locations
Dates
study started
completion around
Principal Investigator
by Rita S. Mehta

Description

Summary

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.

Official Title

A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer

Details

Keywords

Stage I Breast Cancer, Breast Neoplasms, Recurrence, Tamoxifen, Letrozole, Exemestane, Anastrozole, Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Breast Radiation Therapy + Endocrine Therapy

Eligibility

Locations

Lead Scientist at UC Irvine

  • Rita S. Mehta
    Health Sciences Professor, Medicine, School of Medicine. Authored (or co-authored) 74 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
NRG Oncology
ID
NCT04852887
Phase
Phase 3 Breast Cancer Research Study
Study Type
Interventional
Participants
Expecting 1670 study participants
Last Updated